Anneliese Js Flatt

Anneliese Js Flatt

Auto-generated profile, based on publicly available information

Anneliese Js Flatt

Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
AFAnneliese J. Flatt
Anneliese J. Flatt
APAmy J. Peleckis
Amy J. Peleckis
CDCornelia Dalton-Bakes
Cornelia Dalton-Bakes
HNHuong-Lan Nguyen
Huong-Lan Nguyen
SISarah Ilany
Sarah Ilany
MRMichael R. Rickels
Michael R. Rickels
Objective: Automated insulin delivery (AID) may benefit individuals with long-standing type 1 diabetes where frequent exposure to hypoglycemia impairs counterregulatory responses. This study assessed the effect of 18 months AID on hypoglycemia avoidance and glucose counterregulatory responses to insulin-induced hypoglycemia in long-standing type 1 diabetes complicated by impaired awareness of hypoglycemia. Methods: Ten participants mean ± standard deviation age 49 ± 16 and diabetes duration 34 ± 16 years were initiated on AID. Continuous glucose monitoring was paired with actigraphy to assess awake- and sleep-associated hypoglycemia exposure every 3 months. Hyperinsulinemic hypoglycemic clamp experiments were performed at baseline, 6, and 18 months postintervention. Hypoglycemia exposure was reduced by 3 months, especially during sleep, with effects sustained through 18 months ( P ≤ 0.001) together with reduced glucose variability ( P < 0.01). Results: Hypoglycemia awareness and severity scores improved ( P < 0.01) with severe hypoglycemia events reduced from median (interquartile range) 3 (3–10) at baseline to 0 (0–1) events/person·year postintervention ( P = 0.005). During the hypoglycemic clamp experiments, no change was seen in the endogenous glucose production (EGP) response, however, peripheral glucose utilization during hypoglycemia was reduced following intervention [pre: 4.6 ± 0.4, 6 months: 3.8 ± 0.5, 18 months: 3.4 ± 0.3 mg/(kg·min), P < 0.05]. There were increases over time in pancreatic polypeptide (Pre:62 ± 29, 6 months:127 ± 44, 18 months:176 ± 58 pmol/L, P < 0.01), epinephrine (Pre: 199 ± 53, 6 months: 332 ± 91, 18 months: 386 ± 95 pg/mL, P = 0.001), and autonomic symptom (Pre: 6 ± 2, 6 months: 6 ± 2, 18 months: 10 ± 2, P < 0.05) responses. Conclusions: AID led to a sustained reduction of hypoglycemia exposure. EGP in response to insulin-induced hypoglycemia remained defective, however, partial recovery of glucose counterregulation was evidenced by a reduction in peripheral glucose utilization likely mediated by increased epinephrine secretion and, together with improved autonomic symptoms, may contribute to the observed clinical reduction in hypoglycemia.

4 September 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
AFAnneliese J.S. Flatt
Anneliese J.S. Flatt
SLStuart A. Little
Stuart A. Little
JSJane Speight
Jane Speight
LLLalantha H. Leelarathna
Lalantha H. Leelarathna
EWEmma Walkinshaw
Emma Walkinshaw
JSJames A.M. Shaw
James A.M. Shaw
OBJECTIVE The HypoCOMPaSS study was designed to test the hypothesis that successful avoidance of biochemical hypoglycemia without compromising overall glycemic control would restore sufficient hypoglycemia awareness to prevent recurrent severe hypoglycemia in the majority of participants with established type 1 diabetes. Before starting the study, we planned to investigate associations between baseline characteristics and recurrent severe hypoglycemia over 2 years’ follow-up. RESEARCH DESIGN AND METHODS A total of 96 adults with type 1 diabetes and impaired awareness of hypoglycemia participated in a 24-week 2 × 2 factorial randomized controlled trial comparing insulin delivery and glucose monitoring modalities, with the goal of rigorous biochemical hypoglycemia avoidance. The analysis included 71 participants who had experienced severe hypoglycemia in the 12-month prestudy with confirmed absence (complete responder) or presence (incomplete responder) of severe hypoglycemia over 24 months’ follow-up. RESULTS There were 43 (61%) complete responders and 28 (39%) incomplete responders experiencing mean ± SD 1.5 ± 1.0 severe hypoglycemia events/person-year. At 24 months, incomplete responders spent no more time with glucose ≤3 mmol/L (1.4 ± 2.1% vs. 3.0 ± 4.8% for complete responders; P = 0.26), with lower total daily insulin dose (0.45 vs. 0.58 units/24 h; P = 0.01) and greater impairment of hypoglycemia awareness (Clarke score: 3.8 ± 2.2 vs. 2.0 ± 1.9; P = 0.01). Baseline severe hypoglycemia rate (16.9 ± 16.3 vs. 6.4 ± 10.8 events/person-year; P = 0.002) and fear of hypoglycemia were higher in incomplete responders. Peripheral neuropathy was more prevalent in incomplete responders (11 [39%] vs. 2 [4.7%]; P < 0.001) with a trend toward increased autonomic neuropathy. CONCLUSIONS Recurrent severe hypoglycemia was associated with higher preintervention severe hypoglycemia rate, fear of hypoglycemia, and concomitant neuropathy.

29 September 2022 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
AFAnneliese J. Flatt
Anneliese J. Flatt
ECElizabeth Chen
Elizabeth Chen
APAmy J. Peleckis
Amy J. Peleckis
CDCornelia Dalton-Bakes
Cornelia Dalton-Bakes
HNHuong-Lan Nguyen
Huong-Lan Nguyen
MRMichael R. Rickels
Michael R. Rickels
Repeated hypoglycemia exposure leads to impaired awareness of hypoglycemia (IAH) and the development of defective counterregulatory responses. To date, only pancreas or islet transplantation has demonstrated normalization of hypoglycemia awareness and the endogenous glucose production (EGP) response to defend against insulin-induced hypoglycemia in long-standing type 1 diabetes (T1D). This study aims to validate clinical metrics of IAH (Clarke score), hypoglycemia severity (HYPO score), glycemic lability (lability index), and continuous glucose monitoring (CGM) as predictors of absent autonomic symptom (AS) recognition and defective glucose counterregulation during insulin-induced hypoglycemia, thus enabling early identification of individuals with compromised physiologic defense against clinically significant hypoglycemia. Forty-three subjects with mean ± standard deviation age 43 ± 13 years and T1D duration 28 ± 13 years, including 32 with IAH and 11 with hypoglycemia awareness (Aware), and 12 nondiabetic control subjects, underwent single-blinded randomized-paired hyperinsulinemic–euglycemic and hypoglycemic clamp experiments. Receiver operating characteristic (ROC) curves and sensitivity analyses were performed to assess metric prediction of absent AS recognition and defective EGP responses to hypoglycemia. Clarke score and CGM measures of hypoglycemia exposure demonstrated good ability to predict absent AS recognition (area under the curve ≥0.80). A composite threshold of IAH–Clarke ≥4 with ROC curve-derived thresholds for CGM measures of hypoglycemia exposure showed high specificity and predictive value in identifying an absent AS response during the hypoglycemic clamp. Metrics demonstrated poor ability to predict defective glucose counterregulation by the EGP response, which was impaired even in the Aware group. Screening for IAH alongside assessment of CGM data can increase the specificity for identifying individuals with absent hypoglycemia symptom recognition who may benefit from further intervention.

28 July 2023 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AFAnneliese J Flatt
Anneliese J Flatt
SSSaba Sheikh
Saba Sheikh
APAmy J Peleckis
Amy J Peleckis
PAPaola Alvarado
Paola Alvarado
DHDenis Hadjiliadis
Denis Hadjiliadis
MRMichael R Rickels
Michael R Rickels
Context Elexacaftor/Tezacaftor/Ivacaftor (ETI; Trikafta™) enhances aberrant cystic fibrosis transmembrane conductance regulator (CFTR) function and may improve the insulin secretory defects associated with a deterioration in clinical outcomes in pancreatic insufficient cystic fibrosis (PI-CF). Objective This longitudinal case-control study assessed changes in β-cell function and secretory capacity measures over two visits in individuals with PI-CF who were initiated on ETI after the baseline visit (2012-2018) and 1) restudied between 2019-2021 (ETI group) vs. 2) those restudied between 2015-2018 and not yet treated with CFTR modulator therapy (controls). Methods Nine ETI participants (mean ± SD age 25 ± 5 years) and eight matched controls were followed up after median(IQR) 5(4-7) and 3(2-3) years, respectively (p < 0.01), with ETI initiation a median of 1 year before follow-up. Clinical outcomes, glucose-potentiated arginine (GPA) and mixed-meal tolerance test (MMTT) measures were assessed with comparisons of within and between group change by non-parametric testing. Results Glucose-potentiated insulin and C-peptide responses to GPA deteriorated in controls but not the ETI group, with C-peptide changes different between groups (p < 0.05). Deterioration in basal proinsulin secretory ratio was observed in controls but improved, as did the maximal arginine-induced proinsulin secretory ratio, in the ETI group (p < 0.05 for all comparisons). During MMTT, early insulin secretion improved as evidenced by more rapid insulin secretory rate kinetics. Conclusion ETI preserves β-cell function in CF through effects on glucose-dependent insulin secretion, proinsulin processing and meal-related insulin secretion. Further work should determine whether early intervention with ETI can prevent deterioration of glucose tolerance in PI-CF.

8 November 2019 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
AFA. J. S. Flatt
A. J. S. Flatt
DBD. Bennett
D. Bennett
CCC. Counter
C. Counter
ABA. L. Brown
A. L. Brown
SWS. A. White
S. A. White
JSJ. A. M. Shaw
J. A. M. Shaw

14 July 2023 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
SMSusan Kohl Malone
Susan Kohl Malone
AMAustin M. Matus
Austin M. Matus
AFAnneliese J. Flatt
Anneliese J. Flatt
APAmy J. Peleckis
Amy J. Peleckis
LGLaura Grunin
Laura Grunin
NGNamni Goel
Namni Goel
Background: This study assessed changes in actigraphy-estimated sleep and glycemic outcomes after initiating automated insulin delivery (AID). Methods: Ten adults with long-standing type 1 diabetes and impaired awareness of hypoglycemia (IAH) participated in an 18-month clinical trial assessing an AID intervention on hypoglycemia and counter-regulatory mechanisms. Data from eight participants (median age = 58 years) with concurrent wrist actigraph and continuous glucose monitoring (CGM) data were used in the present analyses. Actigraphs and CGM measured sleep and glycemic control at baseline (one week) and months 3, 6, 9, 12, 15, and 18 (three weeks) following AID initiation. HypoCount software integrated actigraphy with CGM data to separate wake and sleep-associated glycemic measures. Paired sample t -tests and Cohen’s d effect sizes modeled changes and their magnitude in sleep, glycemic control, IAH (Clarke score), hypoglycemia severity (HYPO score), hypoglycemia exposure (CGM), and glycemic variability (lability index [LI]; CGM coefficient-of-variation [CV]) from baseline to 18 months. Results: Sleep improved from baseline to 18 months (shorter sleep latency [ P < .05, d = 1.74], later sleep offset [ P < .05, d = 0.90], less wake after sleep onset [ P < .01, d = 1.43]). Later sleep onset ( d = 0.74) and sleep midpoint ( d = 0.77) showed medium effect sizes. Sleep improvements were evident from 12 to 15 months after AID initiation and were preceded by improved hypoglycemia awareness (Clarke score [ d = 1.18]), reduced hypoglycemia severity (HYPO score [ d = 2.13]), reduced sleep-associated hypoglycemia (percent time glucose was < 54 mg/dL, < 60 mg/dL,< 70 mg/dL; d = 0.66-0.81), and reduced glucose variability (LI, d = 0.86; CV, d = 0.62). Conclusion: AID improved sleep initiation and maintenance. Improved awareness of hypoglycemia, reduced hypoglycemia severity, hypoglycemia exposure, and glucose variability preceded sleep improvements. This trial is registered with ClinicalTrials.gov NCT03215914 https://clinicaltrials.gov/ct2/show/NCT03215914 .